Novo Nordisk Stock Plunges After Obesity Drug Trial Disappoints
Novo Nordisk stock plunged over 20% after its new obesity drug, CagriSema, showed less weight loss than expected in a clinical trial. This setback benefits competitor Eli Lilly, whose similar drug, Zepbound, may now gain a market advantage.
Novo Nordisk Stock Plunges After Obesity Drug Trial Disappoints Read More »